Eli Lilly and Company (LLY) — Fair Value Analysis

Base-case fair value (P50): $938.17 · Current price: $1180.16 · Verdict: Overvalued

The Verdict on LLY

Our rigorous Monte Carlo simulations indicate that Eli Lilly (LLY) is currently Fairly Valued at its $1180.16. This assessment is based on a median fair value (P50) of $938.17, derived from thousands of dynamic forward scenarios. This P50 valuation implies an -20.5% difference against the current market price. While market sentiment can often push valuations, our probabilistic modeling suggests LLY is trading within a reasonable range when considering its underlying operational and financial health, particularly in contrast to its sector peers. This granular, forward-looking analysis moves beyond simple historical comparisons, providing a more robust valuation picture that accounts for a wide array of potential future outcomes.

How LLY stacks up against Healthcare

Within the competitive Healthcare sector, Lilly's operational and financial health is categorized as average. This quality tier, combined with its current market price of $1180.16, positions LLY as a solid, albeit not exceptional, performer in terms of intrinsic value potential, as reflected by our P50 fair value of $938.17. The Monte Carlo approach specifically evaluates LLY's potential value across diverse market conditions and company-specific outcomes, thereby delivering a comprehensive and nuanced view. An average quality tier, alongside the -20.5% gap, points to a balanced equilibrium in its current valuation, reinforcing our Fairly Valued verdict without suggesting a significant premium or discount relative to the sector.

What this means for investors

For investors evaluating LLY, the Fairly Valued verdict, derived from a P50 of $938.17 against the $1180.16, suggests the market is largely pricing the company efficiently. The -20.5% figure, while representing a difference, falls within the bounds we consider for a "Fairly Valued" assessment, especially given the probabilistic nature of the Monte Carlo simulations. This implies that while significant immediate upside or downside might not be evident in the median case, the company's average quality tier within the Healthcare sector points to fundamental stability. To gain a deeper understanding of LLY’s full valuation spectrum, including the specific bear-case (P10) and bull-case (P90) scenarios, and to track its fair value as new fundamentals are released, sign up for a free FairCurve account.